drugset
drugset / Trial / NCT02930967

Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

NCT02930967 ↗

Phase 1 Unknown 20 enrolled China Meitan General Hospital Marino Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A Chimeric Switch Receptor, which was constructed by fusing the PD1 extracellular ligand binding domain to the CD28 intracellular costimulatory domain, was designed to target PD-L 1 positive tumors . In this single-arm, open-label, one center, dose escalation clinical study, the main purpose is to determine the safety and efficacy of infusion of autologous Chimeric Switch Receptor modified T cells (CSR T) in adult patients with PD-L1 positive, recurrent or metastatic malignant tumors.

Timeline

Start
2016-08
Primary completion
2018-08
Completion
2019-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CSR T Cell therapy 50000 cells/kg Intravenous
Subject CSR T Cell therapy 1e+07 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified — —

Indications

No indication recorded.